Kanneganti Lab

🚨Out now @jbiolchem:
@OIndari, @ThiruKanneganti & the team show PANoptosis persists even when key pore-forming proteins (GSDMD, GSDME, MLKL) are deleted, challenging "executioner"-based definitions of #celldeath and favoring upstream therapeutic targets.
doi.org/10.1016/j.jbc.…

📘@Cell_Res: Inflammasome & PANoptosome sensor structures, lack of complete structures for these assembled complexes, and how advances in cryo-EM/cryo-ET are working to fill the gap. Congrats to R. Nagampalli, S. Upadhyay, S. Resende, & @ThiruKanneganti!
rdcu.be/EGZTPyRBbWfa

Now @emboreports! @bhesh82 @ThiruKanneganti & team surprisingly saw NLRP1-mediated PANoptosis inhibition by LPS via type I IFN production. IFNs also directly inhibit the cell death, suggesting IFNα/β as potential therapeutics in NLRP1-driven #inflammation
link.springer.com/article/10.103…

🚨Out today @J_Immunol: @rummansarkar, @ThiruKanneganti, and the team show that NAD+ depletion occurs in multiple lytic #cell death pathways, but restoring NAD+ selectively inhibits PANoptosis, providing a key link between #metabolic stress and PANoptosis:
academic.oup.com/jimmunol/artic…

📣 Out now @CellChemBiol!
@kzengeler and @ThiruKanneganti detail experimental evidence for #inflammatory #cell death, PANoptosis, across immune, non-immune, and cancer cell types, with #translational impacts in #infection, #inflammation, and #cancers:
sciencedirect.com/science/articl…